Dmitrij Hristodorov PhD
General Partner
Targeting RyR: A novel mechanism to correct calcium channel dysfunction
Decades of foundational research have made it possible to drug ryanodine receptors (RyRs), ion channels that regulate the intracellular flow of calcium in nearly all cell types and are essential for muscle contraction.
RyCarma is developing a novel class of therapeutics, called Rycals®, for serious diseases with high unmet need in which ryanodine receptors play a critical role in disease progression.
Industry
Biotech
Status
Current
Forbion brings analytical rigor, strategic thinking and leadership support, which can be a challenging balance, especially during challenging capital markets. Since joining RyCarma in an interim role in May 2024, I’ve worked closely with Forbion on numerous initiatives, including successfully completing a non-interventional endpoints study in a rare disease (RYR1-RM) with significant unmet need, and preparing for a Phase 2 study in RYR1-RM, expected to launch in early 2026.Adam Rosenberg
CEO
Forbion team
Geert-Jan Mulder MD
Managing Partner